Table 6. Regression models for CMR variables stratified by race.
CMR Variable | Interaction Term p value | White N=404 | Black N=170 | Hispanic N=229 | Asian N=128 |
---|---|---|---|---|---|
| |||||
LV Mass(g) | 0.04 | -4±1* | -3±1‡ | -2±1‡ | -0.04±1.3 |
LV Mass Index(g/m2) | 0.27 | -2.2±0.4* | -1.8±0.6† | -1.5±0.5† | -0.9±0.6 |
LV End Diastolic Volume(ml) | 0.21 | -3±1† | -2±1 | -2±1 | -0.06±1.5 |
LV End Diastolic Volume Index(ml/m2) | 0.62 | -1.8±0.5* | -1.3±0.7‡ | -1.5±0.6‡ | -0.8±0.7 |
LV End Systolic Volume(ml) | 0.02 | -2±1† | -0.4±0.8 | -2±1† | 1±1 |
LV End Systolic Volume Index(ml/m2) | 0.05 | -0.9±0.3† | -0.4±0.4 | -1.2±0.3† | 0.04±0.4 |
Mass/Volume Ratio(g/ml) | 0.99 | -0.004±0.009 | 0.001±0.01 | -0.005±0.01 | -0.002±0.01 |
Stroke Volume(ml) | 0.30 | -2±1‡ | -2±1 | -0.2±0.7 | -0.8±0.9 |
LV Ejection Fraction(%) | 0.03 | 0.2±0.3 | -0.2±0.4 | 0.8±0.3‡ | -0.4±0.4 |
Noted as B±SEM. P values:
p≤0.0005,
p≤0.005,
p≤0.05.
A 1 unit increase in log2 leptin represents a doubling of the leptin level. Adjusted for age, gender, systolic blood pressure, anti-hypertensive usage, LDL, HDL, hyperlipidemia medication usage, diabetes, diabetic medication usage, chronic kidney disease, current alcohol and tobacco use, adiponectin and BMI.